NEW YORK ( TheStreet) -- Within the last few days of writing this commentary, and prior to celebrating our July Fourth independence, two significant scandals have been resolved, one in the banking industry and another in pharmaceuticals.
GlaxoSmithKline (GSK) agreed to plead guilty to misdemeanor criminal charges and pay $3 billion to settle what government officials described as the largest case of health care fraud in U.S. history.
GSK targeted the antidepressant Paxil to under-age patients, pushed Wellbutrin for uses it was not approved for, falsified articles, used illegal kickbacks, and also failed to give the U.S. Food and Drug Administration safety data about its diabetes drug Avandia.
Barclays PLC (BCS), the huge international banking concern of the U.K., has agreed to pay $453 million in fines to the U.S. Justice Department and the U.K.'s Financial Services Authority over charges it manipulated the LIBOR, a short-term interest rate used to calculate consumer bank loans, from mortgages to credit cards.
|Barclays Chief Executive Bob Diamond Stepping Down|
Their stock values will be diminished in the near term.
There will be announcements of major policy, process and practice improvements prior to the year's end.
However, neither company will go away. They are both icons with substantial assets to endure the latest penalties, downturn in business and reputation dips.
Banking and big pharma take another self-induced hit of scandalous practices. In 2009,
(PFE) was hit with a $2.3 billion settlement for improperly marketing 13 drugs. Barclays' upset comes only months after the $2 billion+ debacle with
(JPM) investment-risk meltdown.
Regulatory and investigative attention will increase.
Advertising, public relations campaigns, legal fees, risk-management efforts and training budgets will go through the roof.
There may be leadership shake-ups and board shuffling and those who stand accused will move on to other companies.
They should be immediately fired or removed;
granted no resignation severance packages or benefits;
all compensation gained during the illicit practices should be clawed back and used to partially pay for the settlements;
they should be banned from holding any executive role in their particular industry for up to 10 years;
should not be allowed to leverage their misconduct into any means of profiteering such as lectures, books, media interviews, consulting, etc.;
company board members should also be immediately removed and undergo the aforementioned punishments including their inability to serve on any other corporate boards for up to 10 years.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV